应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
IMRX Immuneering Corp
盘后交易 03-19 16:50:23 EDT
4.86
+0.08
+1.67%
盘后
4.86
+0.00
0.00%
16:10 EDT
最高
4.91
最低
4.67
成交量
110.74万
今开
4.70
昨收
4.78
日振幅
5.02%
总市值
3.14亿
流通市值
2.64亿
总股本
6,457万
成交额
533.17万
换手率
2.04%
流通股本
5,441万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Immuneering公布2025年第四季度及全年财务业绩并更新业务进展
美股速递 · 03-06
Immuneering公布2025年第四季度及全年财务业绩并更新业务进展
Immuneering Corporation盘中异动 股价大跌5.26%
市场透视 · 01-12
Immuneering Corporation盘中异动 股价大跌5.26%
优于标准疗法但仍不敌竞品 Immuneering(IMRX.US)胰腺癌疗法2期数据公布后盘后重挫21%
智通财经 · 01-08
优于标准疗法但仍不敌竞品 Immuneering(IMRX.US)胰腺癌疗法2期数据公布后盘后重挫21%
Immuneering公布一线胰腺癌患者接受Atebimetinib联合Mgnp治疗的12个月总生存率高达64%
美股速递 · 01-08
Immuneering公布一线胰腺癌患者接受Atebimetinib联合Mgnp治疗的12个月总生存率高达64%
Immuneering将在2026年1月7日公布一线胰腺癌患者接受Atebimetinib + Mgnp治疗的2a期临床试验12个月整体生存数据
美股速递 · 2025-12-23
Immuneering将在2026年1月7日公布一线胰腺癌患者接受Atebimetinib + Mgnp治疗的2a期临床试验12个月整体生存数据
Immuneering公司推进III期Atebimetinib试验,目标为首例一线转移性胰腺癌患者给药,同时获得FDA和EMA的对齐
美股速递 · 2025-12-18
Immuneering公司推进III期Atebimetinib试验,目标为首例一线转移性胰腺癌患者给药,同时获得FDA和EMA的对齐
Immuneering预计将在2026年中期开始全球III期注册试验Mapkeeper 301的首位患者的给药
美股速递 · 2025-12-18
Immuneering预计将在2026年中期开始全球III期注册试验Mapkeeper 301的首位患者的给药
Immuneering Corporation盘中异动 早盘大幅下挫5.43%
市场透视 · 2025-11-14
Immuneering Corporation盘中异动 早盘大幅下挫5.43%
Immuneering Corporation盘中异动 下午盘股价大涨5.04%报6.57美元
市场透视 · 2025-10-31
Immuneering Corporation盘中异动 下午盘股价大涨5.04%报6.57美元
Immuneering Corporation盘中异动 下午盘股价大涨5.20%报6.27美元
市场透视 · 2025-10-16
Immuneering Corporation盘中异动 下午盘股价大涨5.20%报6.27美元
Immuneering Corporation盘中异动 大幅下跌5.06%
市场透视 · 2025-10-13
Immuneering Corporation盘中异动 大幅下跌5.06%
Immuneering Corporation盘中异动 早盘急速下跌5.14%报6.64美元
市场透视 · 2025-10-01
Immuneering Corporation盘中异动 早盘急速下跌5.14%报6.64美元
Immuneering Corp将于2025年9月29日周一讨论Atebimetinib联合Mgnp治疗一线胰腺癌患者2a期临床试验的最新总体生存期数据
美股速递 · 2025-09-27
Immuneering Corp将于2025年9月29日周一讨论Atebimetinib联合Mgnp治疗一线胰腺癌患者2a期临床试验的最新总体生存期数据
Immuneering Corp宣布完成1.75亿美元A类普通股承销公开发行定价,同时向Sanofi进行2500万美元私募配售
美股速递 · 2025-09-25
Immuneering Corp宣布完成1.75亿美元A类普通股承销公开发行定价,同时向Sanofi进行2500万美元私募配售
Immuneering Corp宣布拟议承销公开发行A类普通股和预付费认股权证,同时向Sanofi进行A类和B类普通股私募配售
美股速递 · 2025-09-25
Immuneering Corp宣布拟议承销公开发行A类普通股和预付费认股权证,同时向Sanofi进行A类和B类普通股私募配售
Immuneering Corp宣布一线胰腺癌患者接受Atebimetinib + Mgnp治疗后9个月总生存率达86%的卓越成果
美股速递 · 2025-09-25
Immuneering Corp宣布一线胰腺癌患者接受Atebimetinib + Mgnp治疗后9个月总生存率达86%的卓越成果
Immuneering Corporation盘中异动 股价大跌5.07%报1.41美元
市场透视 · 2025-03-04
Immuneering Corporation盘中异动 股价大跌5.07%报1.41美元
Immuneering Corporation盘中异动 临近午盘快速跳水5.45%
市场透视 · 2025-03-04
Immuneering Corporation盘中异动 临近午盘快速跳水5.45%
Immuneering Corporation盘中异动 早盘股价大跌5.11%
市场透视 · 2025-02-25
Immuneering Corporation盘中异动 早盘股价大跌5.11%
Immuneering Corporation盘中异动 早盘股价大涨5.26%报1.80美元
市场透视 · 2025-02-22
Immuneering Corporation盘中异动 早盘股价大涨5.26%报1.80美元
加载更多
公司概况
公司名称:
Immuneering Corp
所属市场:
NASDAQ
上市日期:
--
主营业务:
Immuneering Corporation于2008年在特拉华州注册成立。该公司是一家临床阶段的肿瘤学公司,寻求为广泛的癌症患者群体开发和商业化通用RAS/RAF药物。该公司的目标是通过对MAPK通路的深度循环抑制来实现这种普遍的RAS/RAF活性,在保留健康细胞的同时冲击癌细胞。公司的包容性方法将公司与狭义靶向精准疗法区分开来,后者仅限于携带特定突变的肿瘤患者。
发行价格:
--
{"stockData":{"symbol":"IMRX","market":"US","secType":"STK","nameCN":"Immuneering Corp","latestPrice":4.86,"timestamp":1773950400000,"preClose":4.78,"halted":0,"volume":1107381,"hourTrading":{"tag":"盘后","latestPrice":4.86,"preClose":4.86,"latestTime":"16:10 EDT","volume":7547,"amount":36678.420000000006,"timestamp":1773951005011,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01673640167364018,"floatShares":54411779,"shares":64569967,"eps":-1.27295,"marketStatus":"盘后交易","change":0.08,"latestTime":"03-19 16:50:23 EDT","open":4.7,"high":4.91,"low":4.67,"amount":5331652.485341,"amplitude":0.050209,"askPrice":4.96,"askSize":1,"bidPrice":4.78,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-1.27295,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1773964800000},"marketStatusCode":4,"adr":0,"listingDate":1627617600000,"exchange":"NASDAQ","adjPreClose":4.78,"preHourTrading":{"tag":"盘前","latestPrice":4.7001,"preClose":4.78,"latestTime":"09:25 EDT","volume":1066,"amount":5060.7439636,"timestamp":1773926735551,"change":-0.0799,"changeRate":-0.016715,"amplitude":0.027176},"postHourTrading":{"tag":"盘后","latestPrice":4.86,"preClose":4.86,"latestTime":"16:10 EDT","volume":7547,"amount":36678.420000000006,"timestamp":1773951005011,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.953247,"impliedVol":1.9766,"impliedVolPercentile":0.8879},"requestUrl":"/m/hq/s/IMRX","defaultTab":"news","newsList":[{"id":"1167323867","title":"Immuneering公布2025年第四季度及全年财务业绩并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1167323867","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167323867?lang=zh_cn&edition=full","pubTime":"2026-03-06 20:46","pubTimestamp":1772801182,"startTime":"0","endTime":"0","summary":"Immuneering Corp(纳斯达克代码:IMRX)今日正式披露了公司2025财年第四季度及全年的财务数据,同时就当前业务发展状况向市场作出通报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4139","BK4539","BK4563"],"gpt_icon":0},{"id":"2603124529","title":"Immuneering Corporation盘中异动 股价大跌5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603124529","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603124529?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:30","pubTimestamp":1768228240,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日22时30分,Immuneering Corporation股票出现异动,股价大幅下跌5.26%。截至发稿,该股报4.41美元/股,成交量4.7832万股,换手率0.07%,振幅0.00%。Immuneering Corporation股票所在的生物技术行业中,整体涨幅为0.00%。Immuneering Corporation公司简介:Immuneering Corp是一家生物制药公司。该公司专有的计算疾病消除技术平台使Immuneering的药物发现计划成为可能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112223040a4bb0dd6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112223040a4bb0dd6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4139","IMRX","BK4563"],"gpt_icon":0},{"id":"2601333347","title":"优于标准疗法但仍不敌竞品 Immuneering(IMRX.US)胰腺癌疗法2期数据公布后盘后重挫21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601333347","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601333347?lang=zh_cn&edition=full","pubTime":"2026-01-08 09:01","pubTimestamp":1767834062,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,生物技术公司Immuneering Corp.在周三盘后交易中暴跌约21%,此前其公布了atebimetinib作为胰腺癌一线疗法的2a期临床试验结果。该公司报告称,接受atebimetinib联合改良版吉西他滨/白蛋白结合型紫杉醇治疗的患者,12个月总生存率为64%。Immuneering特别指出,在超过10%的患者中仅观察到两种3级不良事件,即中性粒细胞减少症和贫血。其中,avutometinib联合疗法此前报告的总缓解率达83%,daraxonarasib则为55%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390162.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"优于标准疗法但仍不敌竞品 Immuneering(IMRX.US)胰腺癌疗法2期数据公布后盘后重挫21%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","IMRX","BK4539","BK4563"],"gpt_icon":0},{"id":"1180103519","title":"Immuneering公布一线胰腺癌患者接受Atebimetinib联合Mgnp治疗的12个月总生存率高达64%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180103519","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180103519?lang=zh_cn&edition=full","pubTime":"2026-01-08 05:01","pubTimestamp":1767819675,"startTime":"0","endTime":"0","summary":"生物科技公司Immuneering Corp (IMRX) 发布了令人瞩目的临床数据,显示其研发的Atebimetinib与Mgnp联合疗法在一线胰腺癌患者群体中取得突破性进展。治疗组患者在12个月时间点的总生存率达到了惊人的64%,这一数据显著超越了现有标准疗法的预期效果。\n胰腺癌作为恶性程度极高的肿瘤类型,长期面临治疗选择有限、患者预后差的挑战。此次公布的生存率数据为这一疾病领域的治疗带来了新的希望,也凸显了Atebimetinib联合疗法的潜在临床价值。该结果可能为后续的注册临床试验奠定重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4563","BK4539","BK4139"],"gpt_icon":0},{"id":"1123783511","title":"Immuneering将在2026年1月7日公布一线胰腺癌患者接受Atebimetinib + Mgnp治疗的2a期临床试验12个月整体生存数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1123783511","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123783511?lang=zh_cn&edition=full","pubTime":"2025-12-23 21:02","pubTimestamp":1766494972,"startTime":"0","endTime":"0","summary":"Immuneering将在2026年1月7日公布一线胰腺癌患者接受Atebimetinib + Mgnp治疗的2a期临床试验12个月整体生存数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4563","BK4539","BK4139"],"gpt_icon":0},{"id":"1137012656","title":"Immuneering公司推进III期Atebimetinib试验,目标为首例一线转移性胰腺癌患者给药,同时获得FDA和EMA的对齐","url":"https://stock-news.laohu8.com/highlight/detail?id=1137012656","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137012656?lang=zh_cn&edition=full","pubTime":"2025-12-18 05:08","pubTimestamp":1766005735,"startTime":"0","endTime":"0","summary":"Immuneering公司推进III期Atebimetinib试验,目标为首例一线转移性胰腺癌患者给药,同时获得FDA和EMA的对齐。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4539","BK4563","BK4139"],"gpt_icon":0},{"id":"1162312611","title":"Immuneering预计将在2026年中期开始全球III期注册试验Mapkeeper 301的首位患者的给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1162312611","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162312611?lang=zh_cn&edition=full","pubTime":"2025-12-18 05:07","pubTimestamp":1766005646,"startTime":"0","endTime":"0","summary":"Immuneering预计将在2026年中期开始全球III期注册试验Mapkeeper 301的首位患者的给药","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4139","BK4539","BK4563"],"gpt_icon":0},{"id":"2583639168","title":"Immuneering Corporation盘中异动 早盘大幅下挫5.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583639168","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583639168?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:32","pubTimestamp":1763130721,"startTime":"0","endTime":"0","summary":"北京时间2025年11月14日22时32分,Immuneering Corporation股票出现波动,股价大幅跳水5.43%。Immuneering Corporation股票所在的生物技术行业中,整体涨幅为0.13%。其相关个股中,Cidara Therapeutics, Inc.、Invivyd, Inc.、Aspire Biopharma Holdings, Inc.涨幅较大,Aspire Biopharma Holdings, Inc.、Clearmind Medicine Inc.、Salarius Pharmaceuticals, Inc.较为活跃,换手率分别为691.61%、36.15%、28.68%,振幅较大的相关个股有60 Degrees Pharmaceuticals, Inc.、Indaptus Therapeutics, Inc.、Mineralys Therapeutics, Inc.,振幅分别为14.53%、11.51%、10.85%。Immuneering Corporation公司简介:Immuneering Corp是一家生物制药公司。该公司专有的计算疾病消除技术平台使Immuneering的药物发现计划成为可能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511142232019504b0db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511142232019504b0db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4563","IMRX","BK4139","BK4539"],"gpt_icon":0},{"id":"2579443199","title":"Immuneering Corporation盘中异动 下午盘股价大涨5.04%报6.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579443199","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579443199?lang=zh_cn&edition=full","pubTime":"2025-10-31 01:12","pubTimestamp":1761844375,"startTime":"0","endTime":"0","summary":"北京时间2025年10月31日01时12分,Immuneering Corporation股票出现波动,股价快速拉升5.04%。截至发稿,该股报6.57美元/股,成交量44.9432万股,换手率0.71%,振幅7.36%。Immuneering Corporation股票所在的生物技术行业中,整体跌幅为0.67%。Immuneering Corporation公司简介:Immuneering Corp是一家生物制药公司。该公司专有的计算疾病消除技术平台使Immuneering的药物发现计划成为可能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031011255974ab899&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031011255974ab899&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMRX","BK4539","BK4563","BK4139"],"gpt_icon":0},{"id":"2575568207","title":"Immuneering Corporation盘中异动 下午盘股价大涨5.20%报6.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2575568207","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575568207?lang=zh_cn&edition=full","pubTime":"2025-10-16 03:11","pubTimestamp":1760555506,"startTime":"0","endTime":"0","summary":"北京时间2025年10月16日03时11分,Immuneering Corporation股票出现波动,股价急速上涨5.20%。截至发稿,该股报6.27美元/股,成交量110.26万股,换手率1.74%,振幅7.38%。Immuneering Corporation股票所在的生物技术行业中,整体涨幅为0.53%。Immuneering Corporation公司简介:Immuneering Corp是一家生物制药公司。该公司专有的计算疾病消除技术平台使Immuneering的药物发现计划成为可能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101603114697303776&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101603114697303776&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMRX","BK4539","BK4563"],"gpt_icon":0},{"id":"2575371852","title":"Immuneering Corporation盘中异动 大幅下跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575371852","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575371852?lang=zh_cn&edition=full","pubTime":"2025-10-13 23:03","pubTimestamp":1760367828,"startTime":"0","endTime":"0","summary":"北京时间2025年10月13日23时03分,Immuneering Corporation股票出现异动,股价大幅下跌5.06%。Immuneering Corporation股票所在的生物技术行业中,整体涨幅为0.28%。其相关个股中,Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025、天境生物、Nanobiotix涨幅较大,Quoin Pharmaceuticals Ltd、Tvardi Therapeutics, Inc.、Salarius Pharmaceuticals, Inc.较为活跃,换手率分别为83.75%、43.01%、31.48%,振幅较大的相关个股有Carisma Therapeutics, Inc.、Cingulate Inc C/Wts 10/12/2026 、Yd Bio Ltd C/Wts 28/08/2030,振幅分别为32.42%、31.57%、27.69%。Immuneering Corporation公司简介:Immuneering Corp是一家生物制药公司。该公司专有的计算疾病消除技术平台使Immuneering的药物发现计划成为可能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013230348972b7ac2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013230348972b7ac2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMRX","BK4139","BK4563","BK4539"],"gpt_icon":0},{"id":"2572559182","title":"Immuneering Corporation盘中异动 早盘急速下跌5.14%报6.64美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2572559182","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2572559182?lang=zh_cn&edition=full","pubTime":"2025-10-01 22:07","pubTimestamp":1759327649,"startTime":"0","endTime":"0","summary":"北京时间2025年10月01日22时07分,Immuneering Corporation股票出现波动,股价大幅下挫5.14%。截至发稿,该股报6.64美元/股,成交量99.6637万股,换手率1.58%,振幅5.57%。Immuneering Corporation股票所在的生物技术行业中,整体涨幅为1.80%。Immuneering Corporation公司简介:Immuneering Corp是一家生物制药公司。该公司专有的计算疾病消除技术平台使Immuneering的药物发现计划成为可能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251001220729a45036e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251001220729a45036e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMRX","BK4563","BK4539"],"gpt_icon":0},{"id":"1167720395","title":"Immuneering Corp将于2025年9月29日周一讨论Atebimetinib联合Mgnp治疗一线胰腺癌患者2a期临床试验的最新总体生存期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1167720395","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167720395?lang=zh_cn&edition=full","pubTime":"2025-09-27 04:01","pubTimestamp":1758916899,"startTime":"0","endTime":"0","summary":"Immuneering Corp计划于2025年9月29日周一就其最近公布的Atebimetinib联合Mgnp治疗一线胰腺癌患者2a期临床试验的总体生存期数据进行讨论。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4539","IMRX","BK4139"],"gpt_icon":0},{"id":"1164778643","title":"Immuneering Corp宣布完成1.75亿美元A类普通股承销公开发行定价,同时向Sanofi进行2500万美元私募配售","url":"https://stock-news.laohu8.com/highlight/detail?id=1164778643","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164778643?lang=zh_cn&edition=full","pubTime":"2025-09-25 12:09","pubTimestamp":1758773367,"startTime":"0","endTime":"0","summary":"Immuneering Corp宣布完成1.75亿美元A类普通股承销公开发行定价,同时向Sanofi进行2500万美元私募配售","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4563","BK4139","BK4539"],"gpt_icon":0},{"id":"1193887538","title":"Immuneering Corp宣布拟议承销公开发行A类普通股和预付费认股权证,同时向Sanofi进行A类和B类普通股私募配售","url":"https://stock-news.laohu8.com/highlight/detail?id=1193887538","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193887538?lang=zh_cn&edition=full","pubTime":"2025-09-25 04:05","pubTimestamp":1758744315,"startTime":"0","endTime":"0","summary":"Immuneering Corp宣布,公司计划进行A类普通股和预付费认股权证的承销公开发行,同时向Sanofi进行A类普通股和B类普通股的私募配售。\n这一融资计划包括两个部分:首先是面向公众投资者的承销发行,涉及A类普通股和预付费认股权证;其次是与法国制药巨头Sanofi同期进行的私募配售交易,涉及A类和B类普通股。\n该公司此次融资举措旨在为其业务发展和研发项目提供资金支持。具体的发行规模、定价和时间安排等详细信息尚待进一步公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4563","BK4539","BK4139"],"gpt_icon":0},{"id":"1157786888","title":"Immuneering Corp宣布一线胰腺癌患者接受Atebimetinib + Mgnp治疗后9个月总生存率达86%的卓越成果","url":"https://stock-news.laohu8.com/highlight/detail?id=1157786888","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157786888?lang=zh_cn&edition=full","pubTime":"2025-09-25 04:02","pubTimestamp":1758744144,"startTime":"0","endTime":"0","summary":"Immuneering Corp宣布一线胰腺癌患者接受Atebimetinib + Mgnp治疗后9个月总生存率达86%的卓越成果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","IMRX","BK4563","BK4139"],"gpt_icon":0},{"id":"2516037876","title":"Immuneering Corporation盘中异动 股价大跌5.07%报1.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516037876","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516037876?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:28","pubTimestamp":1741102100,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日23时28分,Immuneering Corporation股票出现异动,股价大幅下挫5.07%。截至发稿,该股报1.41美元/股,成交量6.3296万股,换手率0.20%,振幅4.39%。Immuneering Corporation股票所在的生物技术行业中,整体涨幅为0.30%。Immuneering Corporation公司简介:Immuneering Corp是一家生物制药公司。该公司拥有独有的计算性疾病抵消技术平台,可实现Immuneering的药物发现项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304232820989bbbcd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304232820989bbbcd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4563","IMRX","BK4539","BK4139"],"gpt_icon":0},{"id":"2516655184","title":"Immuneering Corporation盘中异动 临近午盘快速跳水5.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516655184","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516655184?lang=zh_cn&edition=full","pubTime":"2025-03-04 00:43","pubTimestamp":1741020186,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日00时43分,Immuneering Corporation股票出现波动,股价快速下挫5.45%。截至发稿,该股报1.56美元/股,成交量10.2418万股,换手率0.33%,振幅4.85%。Immuneering Corporation股票所在的生物技术行业中,整体跌幅为0.38%。Immuneering Corporation公司简介:Immuneering Corp是一家生物制药公司。该公司拥有独有的计算性疾病抵消技术平台,可实现Immuneering的药物发现项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503040043069637cb7a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503040043069637cb7a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMRX","BK4139","BK4539","BK4563"],"gpt_icon":0},{"id":"2514773042","title":"Immuneering Corporation盘中异动 早盘股价大跌5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514773042","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514773042?lang=zh_cn&edition=full","pubTime":"2025-02-25 00:01","pubTimestamp":1740412884,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日00时01分,Immuneering Corporation股票出现波动,股价大幅下跌5.11%。截至发稿,该股报1.67美元/股,成交量10.2635万股,换手率0.33%,振幅6.25%。Immuneering Corporation股票所在的生物技术行业中,整体涨幅为0.16%。Immuneering Corporation公司简介:Immuneering Corp是一家生物制药公司。该公司拥有独有的计算性疾病抵消技术平台,可实现Immuneering的药物发现项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225000124a25229d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225000124a25229d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMRX","BK4139","BK4563","BK4539"],"gpt_icon":0},{"id":"2513297302","title":"Immuneering Corporation盘中异动 早盘股价大涨5.26%报1.80美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513297302","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513297302?lang=zh_cn&edition=full","pubTime":"2025-02-22 00:24","pubTimestamp":1740155086,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日00时24分,Immuneering Corporation股票出现异动,股价大幅上涨5.26%。截至发稿,该股报1.80美元/股,成交量13.5951万股,换手率0.44%,振幅5.32%。Immuneering Corporation股票所在的生物技术行业中,整体涨幅为0.33%。Immuneering Corporation公司简介:Immuneering Corp是一家生物制药公司。该公司拥有独有的计算性疾病抵消技术平台,可实现Immuneering的药物发现项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222002446a24ec96e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222002446a24ec96e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4563","IMRX","BK4539","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immuneering.com","stockEarnings":[{"period":"1week","weight":-0.154},{"period":"1month","weight":-0.0304},{"period":"3month","weight":-0.157},{"period":"6month","weight":-0.4838},{"period":"1year","weight":1.8452},{"period":"ytd","weight":-0.2736}],"compareEarnings":[{"period":"1week","weight":-0.022},{"period":"1month","weight":-0.0298},{"period":"3month","weight":-0.0222},{"period":"6month","weight":-0.0034},{"period":"1year","weight":0.179},{"period":"ytd","weight":-0.03}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Immuneering Corporation于2008年在特拉华州注册成立。该公司是一家临床阶段的肿瘤学公司,寻求为广泛的癌症患者群体开发和商业化通用RAS/RAF药物。该公司的目标是通过对MAPK通路的深度循环抑制来实现这种普遍的RAS/RAF活性,在保留健康细胞的同时冲击癌细胞。公司的包容性方法将公司与狭义靶向精准疗法区分开来,后者仅限于携带特定突变的肿瘤患者。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.22671},{"month":2,"riseRate":0.6,"avgChangeRate":-0.02029},{"month":3,"riseRate":0.2,"avgChangeRate":0.039415},{"month":4,"riseRate":0.25,"avgChangeRate":-0.2067},{"month":5,"riseRate":0.25,"avgChangeRate":0.005771},{"month":6,"riseRate":0.75,"avgChangeRate":0.3519},{"month":7,"riseRate":0.75,"avgChangeRate":0.027683},{"month":8,"riseRate":0.4,"avgChangeRate":0.157517},{"month":9,"riseRate":0.8,"avgChangeRate":0.592866},{"month":10,"riseRate":0.2,"avgChangeRate":-0.073665},{"month":11,"riseRate":0.4,"avgChangeRate":-0.104912},{"month":12,"riseRate":0.4,"avgChangeRate":-0.101218}],"exchange":"NASDAQ","name":"Immuneering Corp","nameEN":"Immuneering Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immuneering Corp(IMRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Immuneering Corp(IMRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Immuneering Corp,IMRX,Immuneering Corp股票,Immuneering Corp股票老虎,Immuneering Corp股票老虎国际,Immuneering Corp行情,Immuneering Corp股票行情,Immuneering Corp股价,Immuneering Corp股市,Immuneering Corp股票价格,Immuneering Corp股票交易,Immuneering Corp股票购买,Immuneering Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immuneering Corp(IMRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Immuneering Corp(IMRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}